Végh Judit, Szilasi Mária, Soós Györgyike, Dévényi Katalin, Dezso Balázs, Soltész Pál, Zeher Margit, Szegedi Gyula, Bodolay Edit
Debreceni Egyetem, Orvos- es Egészségtudományi Centrum, Altalános Orvosi Kar, III. Belgyógyászati Klinika, Immunológiai Tanszék.
Orv Hetil. 2005 Nov 27;146(48):2435-43.
The authors analyzed the incidence of interstitial lung disease in mixed connective tissue disease. They were seeking an answer to the following problems: the nature of the pathological course of mixed connective tissue disease complicated by and the therapy to be used in interstitial lung disease.
179 patients were followed up during a period of 15.9 +/- 6.1 years. Interstitial lung disease was diagnosed using high resolution computed tomography. The diagnosis of interstitial lung disease was not obvious in 5 patients thus open lung biopsy was performed, which confirmed common interstitial pneumonitis. The patients were followed-up, and the data of computed tomography and respiratory function tests were detected 6 months, and then 4 years after the acute lung disease complicated by mixed connective tissue disease.
Out of the 179 mixed connective tissue disease patients 96 (53.6%) had interstitial lung disease. The onset of interstitial lung disease was the most frequent in the 2-4 years of the disease. Four years after the first appearance of interstitial lung disease severe fibrosis was diagnosed in 24 patients (25%). A honey comb formation in the lung developed only in one patient. For the treatment of interstitial lung disease, corticosteroid treatment had to be combined with cyclophosphamide in 51 cases. In 4 patients (24%), pulmonary arterial hypertension evolved 2-4 years following interstitial lung disease. The high pulmonary arterial pressure decreased using pulsed corticosteroid treatment, cyclophosphamide, prostacyclin analogue, anticoagulants therapy and the 4 patients stay alive. The pulmonary arterial hypertension was caused by obliterative vasculopathy.
Pulmonary involvement is found in more than half of the patients with mixed connective tissue disease. Early diagnosis of interstitial lung disease is possible by computed tomography. Interstitial lung disease can be treated by the combination of corticosteroids and cyclophosphamide. The authors were the first to detect the coexistence of interstitial lung disease and pulmonary arterial hypertension in mixed connective tissue disease. Subsequent respiratory alterations in these patient necessitate regular patient follow up.
作者分析了混合性结缔组织病中间质性肺病的发病率。他们试图回答以下问题:混合性结缔组织病并发间质性肺病的病理过程本质以及针对间质性肺病应采用的治疗方法。
对179例患者进行了为期15.9±6.1年的随访。使用高分辨率计算机断层扫描诊断间质性肺病。5例患者间质性肺病诊断不明确,因此进行了开胸肺活检,确诊为普通型间质性肺炎。对患者进行随访,在混合性结缔组织病并发急性肺病后6个月及4年时检测计算机断层扫描和呼吸功能测试数据。
179例混合性结缔组织病患者中,96例(53.6%)患有间质性肺病。间质性肺病发病最常见于疾病的2至4年。间质性肺病首次出现4年后,24例患者(25%)被诊断为严重纤维化。仅1例患者肺部出现蜂窝状改变。对于间质性肺病的治疗,51例患者必须将皮质类固醇治疗与环磷酰胺联合使用。4例患者(24%)在间质性肺病发生2至4年后出现肺动脉高压。使用脉冲皮质类固醇治疗、环磷酰胺、前列环素类似物、抗凝治疗后,肺动脉高压降低,4例患者存活。肺动脉高压由闭塞性血管病引起。
超过半数的混合性结缔组织病患者存在肺部受累。通过计算机断层扫描可早期诊断间质性肺病。间质性肺病可通过皮质类固醇和环磷酰胺联合治疗。作者首次发现混合性结缔组织病中间质性肺病与肺动脉高压并存。这些患者随后的呼吸改变需要定期对患者进行随访。